Lakshman A, et al. – Researchers aspired to detect the efficacy of daratumumab–based combination therapies (DCTs) in patients with relapsed/refractory multiple myeloma (RRMM) treated outside of clinical trials. Findings of this study highlighted the efficacy DCTs in RRMM. It was noted that ORR and progression free survival (PFS) in heavily pre–treated patients were lower than those reported in clinical trials.